

SAGITTARIUS how does the clinical study work?

SAGITTARIUS aims to make post-surgical care for high-risk stage II and stage III colon cancer more effective and less invasive, by combining molecular analysis on tumour tissue from a standard biopsy with a liquid biopsy test.

LIQUID BIOPSY is a pioneering test that detects any tumour DNA present in a patient's blood following surgery.

Here's what happens

1

The **SAGITTARIUS** experts will analyse each participating patient's tumour to determine its specific genetic profile; the results will be used to create a tailor-made liquid biopsy test for each patient.

2

These tests will help researchers detect any traces of tumour DNA in the patients' blood following surgery; these indicate the presence of micrometastatic cells that can't be detected by radiological examinations.

Why take part in this study?

- 50% chance of receiving customised treatment
- Standard treatment that complies with the top guidelines
- Continuous monitoring and adjustment of therapy
- By taking part you will contribute to collecting data that will improve treatment for you and future patients

Do you have high-risk stage two or operable stage three colon cancer?
 You haven't undergone surgery yet, or you were operated on a week ago at most?
 Contact one of our clinical centres to get more information and to explore the possibility of taking part, in consultation with your doctor.



3

If the test is POSITIVE

Standard chemotherapy

Customised therapy
(molecular targeted therapy or immunotherapy based on the molecular characteristics of the tumour)

If the test is NEGATIVE

Therapy chosen by the physician

"Wait and see" approach

The patients who receive customised treatment and the "wait and see" group will undergo regular liquid biopsy testing and, based on the results, the **SAGITTARIUS** project's physicians may adjust their treatment.

<https://sagittarius-horizon.eu/en/the-clinical-network/>